IRIS
RIVARA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.160
AS - Asia 6.269
EU - Europa 5.114
SA - Sud America 906
AF - Africa 328
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 19.786
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.960
SG - Singapore 2.309
CN - Cina 1.778
IT - Italia 1.067
VN - Vietnam 994
FI - Finlandia 786
BR - Brasile 708
IE - Irlanda 692
SE - Svezia 656
DE - Germania 519
HK - Hong Kong 462
UA - Ucraina 340
FR - Francia 236
ZA - Sudafrica 219
NL - Olanda 208
TR - Turchia 177
GB - Regno Unito 164
CA - Canada 124
RU - Federazione Russa 111
IN - India 109
AT - Austria 81
AR - Argentina 67
BE - Belgio 65
BD - Bangladesh 64
CI - Costa d'Avorio 51
IQ - Iraq 51
MX - Messico 50
JP - Giappone 49
PL - Polonia 47
ID - Indonesia 42
ES - Italia 41
KR - Corea 35
PK - Pakistan 30
CZ - Repubblica Ceca 27
PH - Filippine 27
CO - Colombia 26
EC - Ecuador 26
VE - Venezuela 23
JO - Giordania 21
MA - Marocco 20
TH - Thailandia 20
CL - Cile 13
UZ - Uzbekistan 13
PE - Perù 12
PY - Paraguay 12
LT - Lituania 11
SA - Arabia Saudita 11
EG - Egitto 9
MY - Malesia 9
BO - Bolivia 8
KE - Kenya 8
TW - Taiwan 8
UY - Uruguay 8
HR - Croazia 7
RO - Romania 7
RS - Serbia 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
HN - Honduras 6
IL - Israele 6
NP - Nepal 6
OM - Oman 6
AL - Albania 5
DO - Repubblica Dominicana 5
PS - Palestinian Territory 5
EE - Estonia 4
HU - Ungheria 4
SI - Slovenia 4
AU - Australia 3
BY - Bielorussia 3
CR - Costa Rica 3
CY - Cipro 3
ET - Etiopia 3
KZ - Kazakistan 3
LB - Libano 3
LV - Lettonia 3
MD - Moldavia 3
NI - Nicaragua 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BG - Bulgaria 2
BH - Bahrain 2
DZ - Algeria 2
GR - Grecia 2
GY - Guiana 2
JM - Giamaica 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
QA - Qatar 2
TG - Togo 2
BB - Barbados 1
BT - Bhutan 1
BW - Botswana 1
CH - Svizzera 1
Totale 19.765
Salva come PNG Salva come JPEG
Città #
Singapore 1.168
Ashburn 846
Chandler 711
Dublin 690
Dallas 593
San Jose 582
Hong Kong 441
Santa Clara 424
Beijing 423
Jacksonville 383
Ann Arbor 350
Parma 346
Ho Chi Minh City 305
Dearborn 270
Boardman 235
Hanoi 211
Johannesburg 204
Nanjing 182
Los Angeles 156
New York 147
Munich 137
Izmir 135
Princeton 135
Lauterbourg 129
Shanghai 125
Hefei 109
Wilmington 103
San Mateo 87
Helsinki 71
Bremen 69
Columbus 68
Vienna 66
Toronto 63
Brussels 61
São Paulo 58
Shenyang 55
Moscow 54
Abidjan 51
Bologna 49
Council Bluffs 49
Hebei 48
Kunming 47
Nanchang 46
Buffalo 45
Jinan 45
Milan 45
Da Nang 43
Tokyo 43
Turku 43
Haiphong 42
The Dalles 42
Frankfurt am Main 41
Düsseldorf 40
Guangzhou 36
London 36
Warsaw 33
Changsha 31
Woodbridge 31
Des Moines 30
Modena 30
Seattle 30
Jiaxing 29
Jakarta 28
Seoul 28
Brescia 27
Montreal 27
Houston 26
Chennai 24
Pune 24
Stockholm 24
Rio de Janeiro 23
Phoenix 22
Tianjin 22
Atlanta 21
Baghdad 21
Nuremberg 21
Belo Horizonte 20
Brooklyn 20
Fremont 20
Ankara 19
Chicago 19
Amsterdam 18
Paris 18
Amman 17
Zhengzhou 17
Denver 16
Norwalk 16
Hangzhou 15
Orem 15
Dong Ket 14
Mexico City 14
Auburn Hills 13
Brno 13
Dhaka 13
Fortaleza 13
Poplar 13
Biên Hòa 12
Lahore 12
Ninh Bình 12
San Francisco 12
Totale 11.906
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 268
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 232
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 228
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 223
2-Aminobenzimidazoles as new potent H3-antagonists 222
Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats 216
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 215
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 213
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 209
New Antimicrobials Targeting Bacterial RNA Polymerase Holoenzyme Assembly Identified with an in Vivo BRET-Based Discovery Platform 208
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 204
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 204
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 202
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 200
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 198
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 196
Aminobenzimidazoles as new potent H3-antagonists 194
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 192
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 190
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 188
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 186
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 181
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 181
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 180
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 177
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 174
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 174
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 173
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 169
Small molecules targeting the eubacterial β-sliding clamp discovered by combined in silico and in vitro screening approaches 168
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 167
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 167
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 166
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 163
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 162
N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability 160
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 156
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 152
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 149
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 148
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 148
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 148
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 148
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 148
An Optimized Workflow for the Discovery of New Antimicrobial Compounds Targeting Bacterial RNA Polymerase Complex Formation 147
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 146
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 145
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 144
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 144
Social stress contagion in rats: Behavioural, autonomic and neuroendocrine correlates 142
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 141
Experimental and Theoretical Analysis of the Interaction of (±)-cis-Ketoconazole with b-Cyclodextrin in the presence of (+)-L-Tartaric Acid 139
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 139
Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. 139
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 138
Development of a GPCR model for SAR interpretation of classical and new H3 antagonists 138
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 138
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 137
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 135
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 135
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 135
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 134
2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists. 134
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 133
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents 133
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 133
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 132
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 131
Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats 131
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 130
Tricyclic Alkylamides as Melatonin Receptor Ligands with Antagonist or Inverse Agonist Activity 129
Histamine H3-antagonists: the basicity of the polar group in quantitative structure-activity and structure-property relationship 129
Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency 127
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 127
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 125
New classes of potent heparanase inhibitors from ligand-based virtual screening 124
Synthesis and characterization of the first inhibitor of: N -acylphosphatidylethanolamine phospholipase D (NAPE-PLD) 120
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 119
Synthesis and biological evaluation of new non-imidazole H(3)-receptor antagonists of the 2-aminobenzimidazole series 119
In vitro characterization of potency, affinity and selectivity of H3-antagonists: from thioperamide to thioperamide unrelated derivatives 119
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 118
Homology models of melatonin receptors: challenges and recent advances. 117
Design, synthesis and SAR of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors 116
Strategies leading to MT2 selective melatonin receptor antagonists. 116
Synthesis, Pharmacological Evaluation and Structure-Activity Relationships of Benzopyran Derivatives with Potent SERM Activity 115
Plasma concentration and brain penetration of the H3-receptor antagonist Thioperamide in rats 115
Three-Dimensional Quantitative Structure-Activity Relationship Studies on Selected MT1 and MT2 Melatonin Receptor Ligands: Requirements for Subtype Selectivity and Intrinsic Activity Modulation 115
Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability 114
In silico drug discovery of melatonin receptor ligands with therapeutic potential 113
H3-receptor antagonists: Synthesis and structure relationships of para- and meta-substituted 4(5)-phenyl-2-((2-(4(5)-imidazolyl)ethyl)thio)imidazoles 113
Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells 113
Investigating drug-gut microbiota interactions: reductive and hydrolytic metabolism of oral glucocorticoids by in vitro artificial gut microbiota 109
Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N -(4-Anilinoquinazolin-6-yl) acrylamide 108
Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity 107
Imidazole H3-antagonists: Relationship between Structure and Ex-vivo binding to Rat Brain H3-Receptors 107
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 107
Structure-Property Relationships on Histamine H3-Antagonists: Binding of Phenyl-substituted Alkylthioimidazole Derivatives to Rat Plasma Proteins 106
Ligands for the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type 106
Totale 15.520
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.644
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.644
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021174 0 0 0 0 0 0 0 0 0 34 97 43
2021/2022759 22 25 13 87 51 19 70 98 51 59 56 208
2022/20232.764 303 265 170 212 275 333 29 157 848 38 92 42
2023/20241.050 58 72 29 37 77 249 74 90 57 76 94 137
2024/20253.696 82 190 244 221 317 384 186 214 491 382 347 638
2025/20267.643 703 922 1.102 806 1.075 441 827 264 981 522 0 0
Totale 20.030